Evolus (EOLS) Competitors $13.99 -0.63 (-4.31%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$13.89 -0.10 (-0.71%) As of 02/21/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EOLS vs. ACLX, AKRO, RYTM, SRRK, IMVT, APLS, VKTX, ACAD, CRNX, and ZLABShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Arcellx (ACLX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Arcellx Akero Therapeutics Rhythm Pharmaceuticals Scholar Rock Immunovant Apellis Pharmaceuticals Viking Therapeutics ACADIA Pharmaceuticals Crinetics Pharmaceuticals Zai Lab Evolus (NASDAQ:EOLS) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk. Do analysts prefer EOLS or ACLX? Evolus presently has a consensus price target of $23.67, suggesting a potential upside of 69.17%. Arcellx has a consensus price target of $105.93, suggesting a potential upside of 66.16%. Given Evolus' higher probable upside, equities research analysts plainly believe Evolus is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13 Does the MarketBeat Community favor EOLS or ACLX? Evolus received 288 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 72.80% of users gave Evolus an outperform vote. CompanyUnderperformOutperformEvolusOutperform Votes35672.80% Underperform Votes13327.20% ArcellxOutperform Votes6882.93% Underperform Votes1417.07% Does the media favor EOLS or ACLX? In the previous week, Evolus and Evolus both had 4 articles in the media. Arcellx's average media sentiment score of 0.96 beat Evolus' score of 0.89 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcellx 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EOLS or ACLX more profitable? Evolus has a net margin of -22.33% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.33% -847.60% -22.15% Arcellx -25.94%-8.28%-5.21% Which has higher valuation & earnings, EOLS or ACLX? Evolus has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$202.09M4.38-$61.69M-$0.91-15.37Arcellx$110.32M31.25-$70.69M-$0.71-89.79 Do insiders & institutionals have more ownership in EOLS or ACLX? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 6.1% of Evolus shares are owned by company insiders. Comparatively, 6.2% of Arcellx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, EOLS or ACLX? Evolus has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. SummaryArcellx beats Evolus on 11 of the 18 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$925.76M$7.05B$5.84B$9.13BDividend YieldN/A2.75%4.75%3.86%P/E Ratio-15.376.1426.7919.19Price / Sales4.38267.62434.5471.84Price / CashN/A65.6738.0134.83Price / Book-38.866.707.644.62Net Income-$61.69M$138.98M$3.19B$246.06M7 Day Performance-5.09%-2.62%-2.12%-2.62%1 Month Performance-0.21%-3.62%-1.11%-2.57%1 Year Performance1.97%-5.67%15.71%12.72% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.8621 of 5 stars$13.99-4.3%$23.67+69.2%+6.3%$925.76M$202.09M-15.37170ACLXArcellx2.0038 of 5 stars$65.23+2.4%$105.93+62.4%+5.4%$3.53B$155.82M-91.8780Upcoming EarningsAKROAkero Therapeutics4.388 of 5 stars$50.52+2.6%$75.86+50.2%+114.1%$3.53BN/A-13.4730Insider TradeRYTMRhythm Pharmaceuticals4.0683 of 5 stars$56.69-1.5%$68.09+20.1%+27.3%$3.48B$77.43M-13.09140Analyst ForecastInsider TradeNews CoverageSRRKScholar Rock3.0386 of 5 stars$37.07-1.5%$40.43+9.1%+141.2%$3.47B$33.19M-15.77140Insider TradeNews CoveragePositive NewsIMVTImmunovant2.4905 of 5 stars$20.33+2.4%$45.90+125.8%-40.9%$3.45BN/A-7.76120APLSApellis Pharmaceuticals4.2176 of 5 stars$27.40-0.2%$46.71+70.5%-59.3%$3.41B$396.59M-13.50770Short Interest ↓VKTXViking Therapeutics4.3667 of 5 stars$30.48+3.3%$97.29+219.2%-4.5%$3.40BN/A-30.4820ACADACADIA Pharmaceuticals3.063 of 5 stars$20.04+1.4%$24.00+19.8%-19.7%$3.33B$726.44M25.69510Upcoming EarningsShort Interest ↓CRNXCrinetics Pharmaceuticals4.103 of 5 stars$35.21-0.1%$72.64+106.3%+2.1%$3.27B$4.01M-9.44210ZLABZai Lab2.5475 of 5 stars$29.00+0.6%$55.00+89.7%+68.2%$3.17B$266.72M-10.472,175Upcoming EarningsAnalyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies Arcellx Competitors Akero Therapeutics Competitors Rhythm Pharmaceuticals Competitors Scholar Rock Competitors Immunovant Competitors Apellis Pharmaceuticals Competitors Viking Therapeutics Competitors ACADIA Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Zai Lab Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EOLS) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
